An exosome product should not be treated as an automatic upgrade to microneedling. The product's source, intended use, evidence and suitability for the way it will be applied all matter. A promising ingredient category does not establish the benefit or safety of an individual add-on.
This article is a guide to evaluating the claim, not an announcement that SkinAlchemy offers exosome treatment.
Start with the exact product
Ask for the product name and what it contains. Exosomes can come from different sources, and cell-conditioned media is not simply another name for one standardised product. Evidence about one formulation cannot automatically support another.
Ask what outcome the add-on is meant to improve compared with microneedling alone. A mechanism described in a laboratory is different from a demonstrated improvement that patients can see, and photographs without a comparison cannot isolate the add-on's contribution.
The route of application matters
A product applied to intact skin and a product used in a way intended to increase absorption should not be assumed equivalent. In its 2026 final notice, Health Canada states that products represented for administration through microneedling or injection are not consistent with cosmetic classification. Health Canada: final notice on exosome product classification, 2026.
The same notice explains that submitting a cosmetic notification does not constitute approval for sale or agreement that a product qualifies as a cosmetic. Ask what regulatory status applies to this exact product and intended use, rather than accepting a general claim that it is registered.
Keep device claims and product claims separate
The US FDA states that it has not authorised microneedling medical devices for use with other products. That is US guidance, but it illustrates an important distinction: the status of a device does not automatically establish the safety of a particular combination. US FDA: microneedling devices.
For any proposed add-on, ask about preparation, sterility, expected reactions and who handles an unexpected response. The extra product should have its own rationale, rather than borrowing credibility from the procedure.
You can decline the extra without abandoning the assessment
Our microneedling page explains the underlying treatment. Whether it suits your skin is a separate decision from whether an additional product offers worthwhile benefit.
For a consultation in London, Ontario, bring the advertisement or product name that caught your attention. Ask what evidence would change the recommendation and what remains uncertain. You should be able to understand the purpose, additional cost and limitations before agreeing. A simpler plan may be entirely appropriate when the extra step has not earned its place.
Related reading
Sources
An exosome product should not be treated as an automatic upgrade to microneedling. The product's source, intended use, evidence and suitability for the way it will be applied all matter. A promising ingredient category does not establish the benefit or safety of an individual add-on.
This article is a guide to evaluating the claim, not an announcement that SkinAlchemy offers exosome treatment.
Start with the exact product
Ask for the product name and what it contains. Exosomes can come from different sources, and cell-conditioned media is not simply another name for one standardised product. Evidence about one formulation cannot automatically support another.
Ask what outcome the add-on is meant to improve compared with microneedling alone. A mechanism described in a laboratory is different from a demonstrated improvement that patients can see, and photographs without a comparison cannot isolate the add-on's contribution.
The route of application matters
A product applied to intact skin and a product used in a way intended to increase absorption should not be assumed equivalent. In its 2026 final notice, Health Canada states that products represented for administration through microneedling or injection are not consistent with cosmetic classification. Health Canada: final notice on exosome product classification, 2026.
The same notice explains that submitting a cosmetic notification does not constitute approval for sale or agreement that a product qualifies as a cosmetic. Ask what regulatory status applies to this exact product and intended use, rather than accepting a general claim that it is registered.
Keep device claims and product claims separate
The US FDA states that it has not authorised microneedling medical devices for use with other products. That is US guidance, but it illustrates an important distinction: the status of a device does not automatically establish the safety of a particular combination. US FDA: microneedling devices.
For any proposed add-on, ask about preparation, sterility, expected reactions and who handles an unexpected response. The extra product should have its own rationale, rather than borrowing credibility from the procedure.
You can decline the extra without abandoning the assessment
Our microneedling page explains the underlying treatment. Whether it suits your skin is a separate decision from whether an additional product offers worthwhile benefit.
For a consultation in London, Ontario, bring the advertisement or product name that caught your attention. Ask what evidence would change the recommendation and what remains uncertain. You should be able to understand the purpose, additional cost and limitations before agreeing. A simpler plan may be entirely appropriate when the extra step has not earned its place.
